Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
79%
Radiation Therapy
64%
Neoplasm
62%
Oropharynx Carcinoma
60%
Non Small Cell Lung Cancer
55%
Programmed Cell Death
55%
Wart Virus
52%
Diseases
46%
Neck
46%
Recurrent Disease
45%
Malignant Neoplasm
36%
Cancer
35%
Cancer Cell
32%
Overall Survival
32%
Lung Cancer
31%
Oropharynx Squamous Cell Carcinoma
30%
Immunotherapy
28%
Dasatinib
25%
Cisplatin
24%
Intensity Modulated Radiation Therapy
23%
Skin Carcinoma
23%
Induction Chemotherapy
22%
Systemic Therapy
22%
In Vitro
21%
Squamous Cell Carcinoma
20%
Epidermal Growth Factor Receptor
20%
Xenograft
19%
Mesenchymal-Epithelial Transition
19%
Cell Line
19%
Biological Marker
18%
Phosphotransferase
18%
Robot-Assisted Surgery
18%
Plummer-Vinson Syndrome
17%
Carcinoma
17%
Clinical Trial
17%
Arm
17%
Chemoradiotherapy
17%
Polo Like Kinase 1
17%
Aurora Kinase
17%
Distant Metastasis
17%
Surgery
16%
Erlotinib
16%
Progression Free Survival
15%
Neck Dissection
15%
Survival Rate
15%
Metastatic Carcinoma
14%
Targeted Therapy
14%
Lung Cancer Cell Line
14%
Immunity
14%
Carboplatin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Squamous Cell Carcinoma
86%
Neoplasm
75%
Non Small Cell Lung Cancer
68%
Epidermal Growth Factor Receptor
58%
Squamous Cell Carcinoma
48%
Malignant Neoplasm
47%
Cisplatin
42%
Dasatinib
40%
Human Papillomavirus
38%
Chemotherapy
34%
Erlotinib
34%
Diseases
33%
Recurrent Disease
31%
Lung Cancer
30%
Small Cell Lung Cancer
29%
Solid Malignant Neoplasm
29%
Overall Survival
29%
Biological Marker
28%
Protein Tyrosine Kinase
25%
Oropharynx Cancer
24%
Oropharynx Carcinoma
24%
Irinotecan
23%
Phosphotransferase
22%
Clinical Trial
20%
Docetaxel
20%
Progression Free Survival
20%
Carboplatin
19%
Imatinib
17%
Head and Neck Cancer
17%
Pharmacokinetic
15%
Maximum Tolerated Dose
14%
Etoposide
14%
Cetuximab
14%
Cytotoxicity
12%
Immunotherapy
12%
Human Papillomavirus Type 16
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Chemoradiation Therapy
11%
Anaplastic Thyroid Carcinoma
11%
Oropharynx Squamous Cell Carcinoma
11%
Histone Deacetylase Inhibitor
11%
Somatomedin B
11%
Nasopharynx Carcinoma
11%
Paclitaxel
11%
Aurora A Kinase
11%
Survival Rate
11%
Polo Like Kinase 1
10%
Distant Metastasis
9%
Lung Adenocarcinoma
9%
Mammalian Target of Rapamycin Inhibitor
9%
Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
58%
High-risk Human Papillomavirus (HR-HPV)
52%
Apoptosis
48%
Non-small Cell Lung Cancer (NSCLC)
46%
Head-and-neck
35%
Cisplatin
33%
Dasatinib
31%
Erlotinib
30%
Tumor
29%
C-Src
28%
Epidermal Growth Factor Receptor
27%
Squamous Carcinoma Cells
27%
Radiotherapy
23%
Squamous Cell Carcinoma (SqCC)
23%
Lung Cancer
21%
Cutaneous Squamous Cell Carcinoma (cSCC)
20%
High Risk
19%
Overall Survival
19%
Induction Chemotherapy
18%
Polo-like Kinase 1 (PLK1)
18%
Distant Metastasis
18%
Phase II Trial
17%
Cyclin-dependent Kinase 2 (CDK2)
17%
C-Met
17%
Phase I Study
17%
Imatinib
17%
Imatinib Mesylate
17%
Irinotecan
17%
EphA2
17%
Head-and-neck Cancer
17%
Progression-free Survival
16%
Src Inhibitor
16%
Squamous Cell Carcinoma of Head
15%
Src Inhibition
15%
Receptor Tyrosine Kinase
15%
Docetaxel
15%
Intensity-modulated Radiation Therapy
14%
Locally Advanced
14%
Radiation Therapy
14%
Notch1
14%
Aurora Kinase A (AURKA)
14%
Cetuximab
14%
Cancer Cells
13%
Phase II Clinical Trial
13%
Aurora Kinase Inhibitor
12%
Partial Response
12%
Induced Apoptosis
12%
Non-small Cell Lung Cancer Cells
12%
Cell Cycle Arrest
12%